A Multi-ingredient Supplement Reduced Markers of Muscle Damage after a Rugby Match in Collegiate Male Players.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

This study aimed to investigate the effect of a multi-ingredient supplement (MIS), containing the extracts of turmeric, chicken meat, and apple and ancient peat, on markers of muscle damage in collegiate male players following a rugby match.

Why It Was Studied

Eccentric exercise and collisions that lead to muscle damage are common place among athletes.

A position-matched, double-blind, randomized, and crossover design was employed in this study.

Who Took Part

According to the abstract, 13 participants were involved.

PubMed indexes the participants as young adults, men only.

A total of 13 participants, eight forward and five backs, with a mean height of 1.76 ± 0.08 m and a mean weight of 86.0 ± 22.8 kg, were included.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Biomarkers, Muscle, Skeletal, Football, Creatine Kinase, L-Lactate Dehydrogenase and Athletes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 13 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Journal of physiological investigation), a journal based in India.

More context: the Copper (Supplement) compound page, all human trials.